AXGN

AxoGen, Inc. [AXGN] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

AXGN Stock Summary

Top AXGN Correlated Resources

AXGN


Top 10 Correlated ETFs

AXGN


Top 10 Correlated Stocks

AXGN


In the News

07:00 29 Nov 2023 AXGN

Axogen, Inc. to Report Third Quarter 2023 Financial Results and Host Conference Call on November 7, 2023

ALACHUA, Fla. and TAMPA, Fla., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report third quarter 2023 financial results on Tuesday, November 7, 2023 before the market opens. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release.

09:46 29 Nov 2023 AXGN

AxoGen (AXGN) Moves 6.8% Higher: Will This Strength Last?

AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

07:00 29 Nov 2023 AXGN

Axogen to Participate at Upcoming Investor Conferences

ALACHUA and TAMPA, Fla., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, Chairman, Chief Executive Officer, and President, will participate in two investor conferences in September.

09:34 29 Nov 2023 AXGN

AxoGen, Inc. (AXGN) Q2 2023 Earnings Call Transcript

AxoGen, Inc. (NASDAQ:AXGN ) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants Adanna Alexander - Investor Relations Consultant Karen Zaderej - Chairman, Chief Executive Officer and President Pete Mariani - Executive Vice President and Chief Financial Officer Conference Call Participants Michael Sarcone - Jefferies Dave Turkaly - JMP Securities Ross Osborn - Cantor Fitzgerald Caitlin Cronin - Canaccord Genuity Chris Pasquale - Nephron Research Operator Greetings. Welcome to the AxoGen, Inc. Reports Second Quarter 2023 Financial Results Conference Call.

06:54 29 Nov 2023 AXGN

AxoGen (AXGN) Reports Q2 Loss, Lags Revenue Estimates

AxoGen (AXGN) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.06 per share a year ago.

07:00 29 Nov 2023 AXGN

Axogen, Inc. to report second quarter 2023 financial results and host conference call on August 7, 2023

ALACHUA, Fla. and TAMPA, Fla., July 26, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report second quarter 2023 financial results on Monday, August 7, 2023 after the market closes. Axogen management will host an investment-community conference call and webcast at 4:30 p.m. ET following the release.

02:49 29 Nov 2023 AXGN

AxoGen: Far More Constructive With Q1 Numbers, Profitability The Next Hurdle

AxoGen is showing potential for growth, and management expects a record $160 million in revenue this year. Focus on core and active accounts has yielded positive results, with YoY growth of 23% and 9% respectively. However, the lack of earnings and catalysts makes it challenging to estimate an accurate valuation, warranting a hold rating for now.

10:57 29 Nov 2023 AXGN

Wall Street Analysts Think AxoGen (AXGN) Could Surge 69.62%: Read This Before Placing a Bet

The mean of analysts' price targets for AxoGen (AXGN) points to a 69.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

04:05 29 Nov 2023 AXGN

Axogen, Inc. to report first quarter 2023 financial results and host conference call on May 9, 2023

ALACHUA, Fla. and TAMPA, Fla., April 18, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2023 financial results on Tuesday, May 9, 2023 before the market opens. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release.

04:00 29 Nov 2023 AXGN

Axogen, Inc. to report fourth quarter 2022 financial results and host conference call on March 14, 2023

ALACHUA, Fla. and TAMPA, Fla., March 02, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report fourth quarter 2022 financial results on Tuesday, March 14, 2023 before the market opens. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release.

AXGN Financial details

Company Rating
Buy
Market Cap
256.11M
Income
-22.59M
Revenue
152.25M
Book val./share
2.27
Cash/share
0.76
Dividend
-
Dividend %
-
Employees
394
Optionable
No
Shortable
Yes
Earnings
07 Nov 2023
P/E
-11.85
Forward P/E
88.86
PEG
5.97
P/S
1.76
P/B
2.74
P/C
8.18
P/FCF
-11.13
Quick Ratio
2.1
Current Ratio
3.28
Debt / Equity
0.69
LT Debt / Equity
0.68
-
-
EPS (TTM)
-0.55
EPS next Y
0.07
EPS next Q
-0.01
EPS this Y
-4.41%
EPS next Y
-112.84%
EPS next 5Y
-96.33%
EPS last 5Y
1.61%
Revenue last 5Y
10.55%
Revenue Q/Q
8.17%
EPS Q/Q
-40.63%
-
-
-
-
SMA20
53.89%
SMA50
6.64%
SMA100
-31.8%
Inst Own
40.69%
Inst Trans
0.54%
ROA
-12%
ROE
-23%
ROC
-0.14%
Gross Margin
82%
Oper. Margin
-16%
Profit Margin
-15%
Payout
-
Shs Outstand
43.04M
Shs Float
32.29M
-
-
-
-
Target Price
-
52W Range
3.45-11.35
52W High
-43.45%
52W Low
+107.33%
RSI
72.64
Rel Volume
0.94
Avg Volume
442.14K
Volume
415.03K
Perf Week
7.24%
Perf Month
48.45%
Perf Quarter
-33.69%
Perf Half Y
-28.59%
-
-
-
-
Beta
0.794
-
-
Volatility
0.11%, 0.93%
Prev Close
4.01%
Price
6.22
Change
4.54%

AXGN Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
2.262.722.813.093.29
Net income per share
-0.6-0.74-0.62-0.68-0.65
Operating cash flow per share
-0.48-0.51-0.24-0.33-0.38
Free cash flow per share
-0.66-3.61-0.81-1.01-0.89
Cash per share
3.142.462.62.041.16
Book value per share
3.963.373.082.732.4
Tangible book value per share
3.933.333.032.662.31
Share holders equity per share
3.963.373.082.732.4
Interest debt per share
0.030.091.371.671.62
Market cap
758.5M701.91M715.41M386.18M419.99M
Enterprise value
734.27M669.52M720.41M420.88M472.13M
P/E ratio
-33.87-24.1-28.84-13.76-15.36
Price to sales ratio
9.046.586.373.033.03
POCF ratio
-42.46-35.32-74.32-28.81-26.14
PFCF ratio
-31-4.96-22.2-9.24-11.25
P/B Ratio
5.165.315.813.434.16
PTB ratio
5.165.315.813.434.16
EV to sales
8.756.276.423.33.41
Enterprise value over EBITDA
-37.32-25.54-36.46-20.09-18.82
EV to operating cash flow
-41.11-33.69-74.84-31.4-29.39
EV to free cash flow
-30.01-4.73-22.36-10.07-12.65
Earnings yield
-0.03-0.04-0.03-0.07-0.07
Free cash flow yield
-0.03-0.2-0.05-0.11-0.09
Debt to equity
00.030.440.60.67
Debt to assets
00.020.270.320.35
Net debt to EBITDA
1.231.24-0.25-1.66-2.08
Current ratio
11.576.476.365.234.13
Interest coverage
-16.97-785.15-21.99-18.74-47.61
Income quality
0.80.680.40.50.55
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.280.290.240.250.27
Research and developement to revenue
0.140.160.160.190.2
Intangibles to total assets
0.010.010.010.010.02
Capex to operating cash flow
0.376.122.352.121.32
Capex to revenue
-0.08-1.14-0.2-0.22-0.15
Capex to depreciation
-7.76-42.28-6.53-5.99-4.38
Stock based compensation to revenue
0.090.10.080.090.11
Graham number
7.337.56.566.475.92
ROIC
-0.14-0.23-0.12-0.13-0.15
Return on tangible assets
-0.14-0.19-0.12-0.14-0.14
Graham Net
3.262.391.130.26-0.46
Working capital
137.91M114.14M122.42M102.76M74.32M
Tangible asset value
145.8M130.64M121.1M109.69M97.35M
Net current asset value
137.76M112.53M67.02M31.58M3.69M
Invested capital
00.030.440.60.67
Average receivables
13.19M16.13M17.28M17.89M20.17M
Average payables
3.88M6.39M6.43M5.26M7.44M
Average inventory
9.65M12.92M13.2M14.61M17.8M
Days sales outstanding
66.6257.9657.2652.0458.43
Days payables outstanding
127.58173.8277.7594.28135.5
Days of inventory on hand
338.42291.62211.9265.71285.76
Receivables turnover
5.486.36.377.016.25
Payables turnover
2.862.14.693.872.69
Inventory turnover
1.081.251.721.371.28
ROE
-0.15-0.22-0.2-0.25-0.27
Capex per share
-0.18-3.1-0.57-0.69-0.51

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.880.90.860.890.96
Net income per share
-0.09-0.13-0.16-0.16-0.1
Operating cash flow per share
-0.020.03-0.170.010.04
Free cash flow per share
-0.12-0.14-0.28-0.1-0.05
Cash per share
1.261.220.890.810.76
Book value per share
2.42.532.292.272.27
Tangible book value per share
2.322.442.22.172.17
Share holders equity per share
2.42.532.292.272.27
Interest debt per share
1.61.691.581.571.59
Market cap
503.27M398.87M402.3M391.33M215.11M
Enterprise value
556.6M451.01M461.66M435.44M251.42M
P/E ratio
-34.35-19.44-14.99-14.69-13.15
Price to sales ratio
13.6211.0310.9710.265.21
POCF ratio
-730.43292.86-54.21.34K132.29
PFCF ratio
-96.14-73.77-33.58-89.22-94.35
P/B Ratio
4.963.954.134.032.2
PTB ratio
4.963.954.134.032.2
EV to sales
15.0612.4712.5911.416.09
Enterprise value over EBITDA
-153-98.67-74.73-71.02-95.85
EV to operating cash flow
-807.84331.14-62.191.49K154.62
EV to free cash flow
-106.32-83.41-38.54-99.28-110.27
Earnings yield
-0.01-0.01-0.02-0.02-0.02
Free cash flow yield
-0.01-0.01-0.03-0.01-0.01
Debt to equity
0.670.670.690.690.69
Debt to assets
0.350.350.350.350.35
Net debt to EBITDA
-14.66-11.41-9.61-7.19-13.84
Current ratio
4.354.134.183.63.28
Interest coverage
-79.59140.2-458.81-46.64-4.87
Income quality
0.16-0.251.05-0.04-0.4
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.240.250.250.250.21
Research and developement to revenue
0.190.190.180.190.17
Intangibles to total assets
0.020.020.020.020.02
Capex to operating cash flow
6.6-4.970.61-16.02-2.4
Capex to revenue
-0.12-0.19-0.12-0.12-0.09
Capex to depreciation
-3.57-5.79-3.66-4.46-2.77
Stock based compensation to revenue
0.10.110.080.140.12
Graham number
2.172.72.852.812.2
ROIC
-0.02-0.03-0.04-0.04-0.03
Return on tangible assets
-0.02-0.03-0.04-0.04-0.02
Graham Net
-0.36-0.49-0.65-0.77-0.82
Working capital
78.91M74.32M67.46M62.24M60.79M
Tangible asset value
98M97.35M93.66M93.1M93.52M
Net current asset value
8.38M3.69M-3.26M-8.31M-9.38M
Invested capital
0.670.670.690.690.69
Average receivables
20.87M21.77M22.23M21.93M22.42M
Average payables
04.48M4.48M00
Average inventory
19.17M19.01M19.38M20.54M22.13M
Days sales outstanding
52.0255.2154.6950.8950.73
Days payables outstanding
0131.37000
Days of inventory on hand
278.57277.06266.27264.43257.58
Receivables turnover
1.731.631.651.771.77
Payables turnover
00.69000
Inventory turnover
0.320.320.340.340.35
ROE
-0.04-0.05-0.07-0.07-0.04
Capex per share
-0.11-0.17-0.11-0.11-0.09

AXGN Frequently Asked Questions

What is AxoGen, Inc. stock symbol ?

AxoGen, Inc. is a US stock , located in Alachua of Fl and trading under the symbol AXGN

What is AxoGen, Inc. stock quote today ?

AxoGen, Inc. stock price is $6.22 today.

Is AxoGen, Inc. stock public?

Yes, AxoGen, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap